Skip to main content

OraSure Tech Value Stock - Dividend - Research Selection

Orasure tech

ISIN: US68554V1089 , WKN: 881351

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV?1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, OMNIgene DISCOVER, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, GenoFIND, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and public health organizations, distributors, government agencies, physicians\' offices, commercial and industrial entities, retail pharmacies, mass merchandisers, and consumers. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Top Penny Stocks To Watch In May 2025

2025-05-30
As May 2025 unfolds, the U.S. stock market is experiencing a mix of optimism and caution, with indices like the S&P 500 and Nasdaq poised for their best monthly performance since 2023 amid ongoing trade discussions and economic data surprises. In this climate, penny stocks—often associated with smaller or newer companies—continue to capture investor interest due to their potential for growth at lower price points. Despite being considered a throwback term, these stocks can offer compelling...

Orasure Technologies: Multiple Shots To Deliver Value

2025-05-28

Orasure Technologies Inc Files For Mixed Shelf Of Up To $300 Million - SEC Filing

2025-05-20
OraSure Technologies Inc: * ORASURE TECHNOLOGIES INC FILES FOR MIXED SHELF OF UP TO$300MILLION - SEC FILINGSource text:Further company coverage: ...

Evercore says 23andMe buyout removes downside case for OraSure

2025-05-20
Evercore ISI believes Regeneron’s (REGN) acquisition of 23andMe for $256M announcement should remove the downside scenario where OraSure’s (OSUR) 23andMe contribution will be zero into perpetuity. Instead, the firm expects 23andMe should continue to be a “meaningful customer going forward” for OraSure. The company has previously disclosed that Regeneron is already an existing customer, which should bode well for a continued relationship between OraSure and 23andMe, the analyst tells investors in

Targeted Genomics Announces Commercial Collaboration with OraSure Technologies for Direct to Consumer (DTC) Celiac Genetic Testing

2025-05-14
IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Targeted Genomics LLC, developer of GlutenID, the first and only U.S. Food and Drug Administration (FDA) cleared direct-to-consumer (DTC) test for celiac disease genetics, today announced a commercial collaboration with OraSure Technologies, Inc. (NASDAQ: OSUR) manufacturer of ORAcollect®·Dx, the only FDA cleared saliva collection device for general over-the-counter (OTC) use. The collaboration expands consumer access to at-home celiac genetic tes

OraSure Technologies First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

2025-05-09
OraSure Technologies ( NASDAQ:OSUR ) First Quarter 2025 Results Key Financial Results Revenue: US$29.9m (down 45% from...

Orasure Technologies, Inc. Announces Resignation of Chief Product Officer Kathleen G. Weber Effective June 30, 2025

2025-05-09
OraSure Technologies, Inc. announced that on May 8, 2025, Kathleen G. Weber notified the company of her resignation as Chief Product Officer, effective June 30, 2025. Ms. Weber?s resignation will be...

Q1 2025 OraSure Technologies Inc Earnings Call

2025-05-08
Q1 2025 OraSure Technologies Inc Earnings Call

OraSure Technologies Inc (OSUR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

2025-05-08
Despite a slight dip in core revenue, OraSure Technologies Inc (OSUR) showcases resilience with strategic investments and international growth.

OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates

2025-05-07
OraSure (OSUR) delivered earnings and revenue surprises of -20% and 0.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?